ASTX-029
| CAS No. | 2095719-92-7 | Cat. No. | BCP32082 |
| Name | ASTX-029 | ||
| Synonyms | ASTX 029;ASTX 029;ERK1/2 inhibitor 2; | ||
| Formula | C29H31ClFN5O5 | M. Wt | 584.04 |
| Description | ASTX029 is a synthetic small molecule inhibitor of extracellular signal-regulated kinases (ERKs) 1/2. ASTX029 has not been previously evaluated in human subjects. The Phase 1 portion of this study will assess safety and determine the maximum tolerated dose, the recommended Phase 2 dose (RP2D), and the recommended dosing regimen of ASTX029 administered orally. The Phase 2 portion will assess preliminary clinical activity in tumors characterized by gene aberrations in the mitogen-activated protein kinase (MAPK) signal pathway that may confer sensitivity to ASTX029. | ||
| Pathways | MAPK Pathway | ||
| Targets | MEK/ERK | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.